Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye's natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye's trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ITEK
- CUSIP: N/A
- Web: www.inotekpharma.com
- Market Cap: $41.87 million
- Outstanding Shares: 27,010,000
- 50 Day Moving Avg: $1.04
- 200 Day Moving Avg: $1.53
- 52 Week Range: $0.85 - $9.78
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.96
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $2.13 per share
- Price / Book: 0.73
- EBIDTA: ($38,560,000.00)
- Return on Equity: -59.26%
- Return on Assets: -33.15%
- Debt-to-Equity Ratio: 0.86%
- Current Ratio: 27.39%
- Quick Ratio: 27.39%
- Average Volume: 1.22 million shs.
- Beta: 2.76
- Short Ratio: 1.58
Frequently Asked Questions for Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)
What is Inotek Pharmaceuticals Corporation's stock symbol?
Inotek Pharmaceuticals Corporation trades on the NASDAQ under the ticker symbol "ITEK."
How were Inotek Pharmaceuticals Corporation's earnings last quarter?
When will Inotek Pharmaceuticals Corporation make its next earnings announcement?
Where is Inotek Pharmaceuticals Corporation's stock going? Where will Inotek Pharmaceuticals Corporation's stock price be in 2017?
4 equities research analysts have issued 12-month price objectives for Inotek Pharmaceuticals Corporation's shares. Their predictions range from $2.00 to $10.00. On average, they anticipate Inotek Pharmaceuticals Corporation's stock price to reach $4.50 in the next year. View Analyst Ratings for Inotek Pharmaceuticals Corporation.
What are analysts saying about Inotek Pharmaceuticals Corporation stock?
Here are some recent quotes from research analysts about Inotek Pharmaceuticals Corporation stock:
- 1. According to Zacks Investment Research, "Inotek Pharmaceuticals Corporation is a biopharmaceutical company. The company is focused on the discovery, development and commercialization of novel therapies to treat glaucoma and diseases of the eye. Inotek Pharmaceuticals Corporation is headquartered in Lexington, Massachusetts. " (9/12/2017)
- 2. HC Wainwright analysts commented, "Phase 2 FDC data release narrowed to July. With the timing of Inotek’s Phase 2 fixed-dose combination (FDC) trial readout nearing, the company issued a release refining that window from mid-2017 to July, as enrollment for the study has now been completed. The market is not expecting a lot after the MATrX-1 study failed to beat placebo in January, but there is still a glimmer of hope for a positive outcome. Given the company’s enterprise value of negative $27M, we see a much stronger case for the upside (potential confirmation of efficacy with the more valuable, in our view, FDC product) versus limited downside." (4/12/2017)
Who are some of Inotek Pharmaceuticals Corporation's key competitors?
Some companies that are related to Inotek Pharmaceuticals Corporation include ProNAi Therapeutics (SRRA), Aeglea BioTherapeutics (AGLE), Pfenex (PFNX), Ergomed PLC (ERGO), Rexahn Pharmaceuticals (RNN), Applied Genetic Technologies Corporation (AGTC), ImmuPharma PLC (IMM), Motif Bio PLC (MTFB), TRACON Pharmaceuticals (TCON), Flex Pharma (FLKS), Endocyte (ECYT), Microbot Medical (MBOT), vTv Therapeutics (VTVT), Dipexium Pharmaceuticals (PLXP), KemPharm (KMPH), Leap Therapeutics (LPTX), Xenon Pharmaceuticals (XENE) and OptiBiotix Health PLC (OPTI).
Who are Inotek Pharmaceuticals Corporation's key executives?
Inotek Pharmaceuticals Corporation's management team includes the folowing people:
- J. Martin Carroll, Independent Chairman of the Board
- David P. Southwell, President, Chief Executive Officer, Director
- Dale Ritter, Vice President—Finance, Principal Financial and Accounting Officer, Treasurer, Secretary
- Rudolf A. Baumgartner M.D., Executive Vice President, Chief Medical Officer
- Timothy Joseph Barberich, Independent Director
- Carsten Boess, Independent Director
- Paul G. Howes, Independent Director
- Patrick Machado J.D., Independent Director
- Gary M. Phillips M.D., Independent Director
When did Inotek Pharmaceuticals Corporation IPO?
(ITEK) raised $40 million in an initial public offering on Wednesday, February 18th 2015. The company issued 6,700,000 shares at $6.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Nomura were co-managers.
Who owns Inotek Pharmaceuticals Corporation stock?
Inotek Pharmaceuticals Corporation's stock is owned by many different of institutional and retail investors. Top institutional investors include RHO Capital Partners Inc. (9.74%), Senzar Asset Management LLC (3.13%), Sphera Funds Management LTD. (1.49%), Columbus Circle Investors (1.41%), Vanguard Group Inc. (1.17%) and Goldman Sachs Group Inc. (0.64%). Company insiders that own Inotek Pharmaceuticals Corporation stock include David P Southwell and J Martin Carroll. View Institutional Ownership Trends for Inotek Pharmaceuticals Corporation.
Who sold Inotek Pharmaceuticals Corporation stock? Who is selling Inotek Pharmaceuticals Corporation stock?
Who bought Inotek Pharmaceuticals Corporation stock? Who is buying Inotek Pharmaceuticals Corporation stock?
Inotek Pharmaceuticals Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., LMR Partners LLP and GSA Capital Partners LLP. Company insiders that have bought Inotek Pharmaceuticals Corporation stock in the last two years include David P Southwell and J Martin Carroll. View Insider Buying and Selling for Inotek Pharmaceuticals Corporation.
How do I buy Inotek Pharmaceuticals Corporation stock?
Shares of Inotek Pharmaceuticals Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Inotek Pharmaceuticals Corporation's stock price today?
MarketBeat Community Rating for Inotek Pharmaceuticals Corporation (NASDAQ ITEK)MarketBeat's community ratings are surveys of what our community members think about Inotek Pharmaceuticals Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Inotek Pharmaceuticals Corporation stock can currently be purchased for approximately $1.55.
Consensus Ratings for Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||3 Hold Ratings, 1 Buy Rating|
|Consensus Rating:||Hold (Score: 2.25)|
|Consensus Price Target: ||$4.50 (190.32% upside)|
Analysts' Ratings History for Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)
(Data available from 9/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|7/12/2017||Canaccord Genuity||Downgrade||Buy -> Hold||Medium|
|7/11/2017||HC Wainwright||Downgrade||Buy -> Neutral||$2.00||High|
|1/3/2017||Piper Jaffray Companies||Downgrade||Overweight -> Neutral||$3.00||N/A|
|12/1/2016||Roth Capital||Initiated Coverage||Buy||$10.00||N/A|
Earnings History for Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)Earnings History by Quarter for Inotek Pharmaceuticals Corporation (NASDAQ ITEK)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/8/2017|| || || || || || || || |
Earnings Estimates for Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)
2017 EPS Consensus Estimate: ($1.27)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)
Insider Ownership Percentage: 11.70%Insider Trades by Quarter for Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)
Institutional Ownership Percentage: 29.16%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|1/6/2017||David P. Southwell||Insider||Buy||60,000||$1.75||$105,000.00|| |
|5/13/2016||J Martin Carroll||Director||Buy||10,000||$9.03||$90,300.00|| |
|2/23/2015||Argeris N Karabelas||Director||Buy||603,832||$6.00||$3,622,992.00|| |
|2/23/2015||Park Bioventures Lp Devon||Major Shareholder||Buy||814,166||$6.00||$4,884,996.00|| |
Headline Trends for Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)
Latest Headlines for Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)
Inotek Pharmaceuticals Corporation (ITEK) Chart for Friday, September, 22, 2017